argenx (Belgian) sells Vyvgart for autoimmune diseases.
argenx SE (ARGX) is expected to report earnings on Thursday, October 29, 2026, after the close. Consensus EPS estimate is $7.62.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-23 | FY2026 Q2 | $7.06 | $13.49 | +91.1% | $2.82B |
| 2026-05-07 | FY2026 Q1 | $4.75 | $12.25 | +157.9% | $2.07B |
| 2026-02-26 | FY2025 Q4 | $6.24 | $14.25 | +128.4% | $3.21B |
| 2025-10-30 | FY2025 Q3 | $4.16 | $5.18 | +24.5% | $1.13B |
| 2025-03-31 | FY2025 Q1 | $2.89 | $2.78 | -3.8% | $790.68M |
| 2024-09-30 | FY2024 Q2 | $-1.07 | $1.52 | +242.1% | $573.24M |
| 2024-06-30 | FY2024 Q1 | $-0.80 | $-0.55 | +31.2% | $901.94M |
| 2024-03-31 | FY2023 Q4 | $-1.70 | $-1.04 | +38.8% | $401.00M |
ARGX has beaten consensus EPS in 7 of its last 8 reported quarters.
ARGX reported Jul 23. The highlights: EPS of $13.49 — a big beat vs the $7.06 estimate (+91%); revenue of $2.82B — a big beat vs the $1.66B consensus (+70%). Focus now shifts to Vyvgart growth and new indications.
See ARGX on the live calendar →